PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

To identify a group of patients who might benefit from the addition of weekly paclitaxel to conventional anthracycline-containing chemotherapy as adjuvant therapy of node-positive operable breast cancer. The predictive value of PAM50 subtypes and the 11-gene proliferation score contained within the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., Bernard, Philip S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2013
Soggetti:
Clinical Trial
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3608881/
https://ncbi.nlm.nih.gov/pubmed/23423445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2416-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi